<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04971148</url>
  </required_header>
  <id_info>
    <org_study_id>HFNC-Flow-004</org_study_id>
    <nct_id>NCT04971148</nct_id>
  </id_info>
  <brief_title>Correlation of Peak Tidal Inspiratory Flow Measured Before and After Extubation in Adult Patients With Hypoxemia</brief_title>
  <official_title>Correlation of Peak Tidal Inspiratory Flow Measured Before and After Extubation in Adult Patients With Hypoxemia, and Patients' Responses to Different Flows Above Their Peak Tidal Inspiratory Flow During High Flow Nasal Cannula Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Vall d'Hebron</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, patients who are ready for extubation and indicated for high-flow nasal&#xD;
      cannula therapy after extubation will be enrolled, the investigators would measure the&#xD;
      patient peak tidal inspiratory flow (PTIF) pre and post extubation to explore the correlation&#xD;
      between the two PTIFs. Moreover, different HFNC flows would be applied, to explore the&#xD;
      patient response in terms of oxygenation and lung aeration to different flow ratios that&#xD;
      matched and are above post-extubation PTIF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High-flow nasal cannula (HFNC) oxygen therapy has been shown to improve oxygenation, reduce&#xD;
      the need for intubation for patients with acute hypoxemic respiratory failure (AHRF) and&#xD;
      avoid reintubation for post-extubation patients who had high-risk factors. HFNC refers to the&#xD;
      delivery of gas at flows that exceed the patient peak inspiratory flow during tidal&#xD;
      breathing, However, patient peak tidal inspiratory flow (PTIF) is found to vary greatly among&#xD;
      different patients, from 20 to 50 L/min, making it difficult to properly set HFNC in a way to&#xD;
      achieve the desired effects. In two recently published studies in intubated patients, PTIF&#xD;
      varied from 25-65 L/min or 40-80 L/min, thus this study aims to investigate the correlation&#xD;
      between pre-extubation PTIF in different modalities of SBT and post-extubation PTIF for adult&#xD;
      patients, who are indicated to use HFNC immediately after extubation. In addition, the&#xD;
      investigators aim to explore the patient response in terms of oxygenation and lung aeration&#xD;
      to different flow ratios that matched and are above post-extubation PTIF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized to receive different HFNC flow settings (matching their peak tidal inspiratory flow [PTIF], 1.33 times of PTIF, 1.67 times of PTIF and 2 times of PTIF)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SpO2/FIO2</measure>
    <time_frame>20 minutes after each flow setting</time_frame>
    <description>Twenty mins after each flow setting, pulse oximetry divided by fraction of inspired oxygen will be used to assess patient's oxygenation response to different flow</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>End-expiratory lung volume assessed by EIT</measure>
    <time_frame>20 minutes after each flow setting</time_frame>
    <description>Twenty mins after each flow setting, electrical impedance tomography (EIT) will be used to assess patient's end -expiratory lung volume 20 mins after each flow setting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>self-evaluated comfort</measure>
    <time_frame>20 minutes after each flow setting</time_frame>
    <description>Twenty mins after each flow setting, patient comfort will be assessed using a visual numerical scale with a score of 0 as the worst and 10 as the best comfort</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Hypoxemic Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>HFNC flow set at patient peak tidal inspiratory flow</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HFNC flow will be set at the level that matches patient peak tidal inspiratory flow</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFNC flow set at 1.33 times of patient peak tidal inspiratory flow</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HFNC flow will be set at the level that is 1.33 times of patient peak tidal inspiratory flow</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFNC flow set at 1.67 times of patient peak tidal inspiratory flow</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HFNC flow will be set at the level that is 1.67 times of patient peak tidal inspiratory flow</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFNC flow set at 2 times of patient peak tidal inspiratory flow</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HFNC flow will be set at the level that is 2 times of patient peak tidal inspiratory flow</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HFNC flow set at patient peak tidal inspiratory flow</intervention_name>
    <description>HFNC flow will be set at the level equal to patient peak tidal inspiratory flow</description>
    <arm_group_label>HFNC flow set at patient peak tidal inspiratory flow</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HFNC flow set at 1.33 times of patient peak tidal inspiratory flow</intervention_name>
    <description>HFNC flow will be set at 1.33 times of patient peak tidal inspiratory flow</description>
    <arm_group_label>HFNC flow set at 1.33 times of patient peak tidal inspiratory flow</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HFNC flow set at 1.67 times of patient peak tidal inspiratory flow</intervention_name>
    <description>HFNC flow will be set at 1.67 times of patient peak tidal inspiratory flow</description>
    <arm_group_label>HFNC flow set at 1.67 times of patient peak tidal inspiratory flow</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HFNC flow set at 2 times of patient peak tidal inspiratory flow</intervention_name>
    <description>HFNC flow will be set 2 times of patient peak tidal inspiratory flow</description>
    <arm_group_label>HFNC flow set at 2 times of patient peak tidal inspiratory flow</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult intubated patients aged between 18 to 90 years&#xD;
&#xD;
          -  Pass spontaneous breathing trial and receive the order to be extubated&#xD;
&#xD;
          -  Have at least one of the indications to use HFNC after extubation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Need to use inhaled epoprostenol via HFNC&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Unable to use resuscitation mask, such as facial trauma, claustrophobia&#xD;
&#xD;
          -  Non-English speaker&#xD;
&#xD;
          -  Inability to verbally communicate&#xD;
&#xD;
          -  Using extracorporeal membrane oxygenation (ECMO)&#xD;
&#xD;
          -  Hemodynamically unstable&#xD;
&#xD;
          -  Difficult airway&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Li, PhD</last_name>
    <phone>312-563-4643</phone>
    <email>jie_li@rush.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brady Scott, PhD</last_name>
    <phone>312-942-6389</phone>
    <email>Jonathan_B_Scott@rush.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Oriol Roca, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Yasuda H, Okano H, Mayumi T, Narita C, Onodera Y, Nakane M, Shime N. Post-extubation oxygenation strategies in acute respiratory failure: a systematic review and network meta-analysis. Crit Care. 2021 Apr 9;25(1):135. doi: 10.1186/s13054-021-03550-4.</citation>
    <PMID>33836812</PMID>
  </reference>
  <results_reference>
    <citation>Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, Prat G, Boulain T, Morawiec E, Cottereau A, Devaquet J, Nseir S, Razazi K, Mira JP, Argaud L, Chakarian JC, Ricard JD, Wittebole X, Chevalier S, Herbland A, Fartoukh M, Constantin JM, Tonnelier JM, Pierrot M, Mathonnet A, Béduneau G, Delétage-Métreau C, Richard JC, Brochard L, Robert R; FLORALI Study Group; REVA Network. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015 Jun 4;372(23):2185-96. doi: 10.1056/NEJMoa1503326. Epub 2015 May 17.</citation>
    <PMID>25981908</PMID>
  </results_reference>
  <results_reference>
    <citation>Rochwerg B, Granton D, Wang DX, Helviz Y, Einav S, Frat JP, Mekontso-Dessap A, Schreiber A, Azoulay E, Mercat A, Demoule A, Lemiale V, Pesenti A, Riviello ED, Mauri T, Mancebo J, Brochard L, Burns K. High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis. Intensive Care Med. 2019 May;45(5):563-572. doi: 10.1007/s00134-019-05590-5. Epub 2019 Mar 19.</citation>
    <PMID>30888444</PMID>
  </results_reference>
  <results_reference>
    <citation>Li J, Jing G, Scott JB. Year in Review 2019: High-Flow Nasal Cannula Oxygen Therapy for Adult Subjects. Respir Care. 2020 Apr;65(4):545-557. doi: 10.4187/respcare.07663. Review.</citation>
    <PMID>32213602</PMID>
  </results_reference>
  <results_reference>
    <citation>Hernández G, Vaquero C, Colinas L, Cuena R, González P, Canabal A, Sanchez S, Rodriguez ML, Villasclaras A, Fernández R. Effect of Postextubation High-Flow Nasal Cannula vs Noninvasive Ventilation on Reintubation and Postextubation Respiratory Failure in High-Risk Patients: A Randomized Clinical Trial. JAMA. 2016 Oct 18;316(15):1565-1574. doi: 10.1001/jama.2016.14194. Erratum in: JAMA. 2016 Nov 15;316(19):2047-2048. Erratum in: JAMA. 2017 Feb 28;317(8):858.</citation>
    <PMID>27706464</PMID>
  </results_reference>
  <results_reference>
    <citation>Hernández G, Vaquero C, González P, Subira C, Frutos-Vivar F, Rialp G, Laborda C, Colinas L, Cuena R, Fernández R. Effect of Postextubation High-Flow Nasal Cannula vs Conventional Oxygen Therapy on Reintubation in Low-Risk Patients: A Randomized Clinical Trial. JAMA. 2016 Apr 5;315(13):1354-61. doi: 10.1001/jama.2016.2711.</citation>
    <PMID>26975498</PMID>
  </results_reference>
  <results_reference>
    <citation>Butt S, Pistidda L, Floris L, Liperi C, Vasques F, Glover G, Barrett NA, Sanderson B, Grasso S, Shankar-Hari M, Camporotaa L. Initial setting of high-flow nasal oxygen post extubation based on mean inspiratory flow during a spontaneous breathing trial. J Crit Care. 2021 Jun;63:40-44. doi: 10.1016/j.jcrc.2020.12.022. Epub 2020 Dec 27.</citation>
    <PMID>33621890</PMID>
  </results_reference>
  <results_reference>
    <citation>Mauri T, Spinelli E, Dalla Corte F, Scotti E, Turrini C, Lazzeri M, Alban L, Albanese M, Tortolani D, Wang YM, Spadaro S, Zhou JX, Pesenti A, Grasselli G. Noninvasive assessment of airflows by electrical impedance tomography in intubated hypoxemic patients: an exploratory study. Ann Intensive Care. 2019 Jul 22;9(1):83. doi: 10.1186/s13613-019-0560-5.</citation>
    <PMID>31332551</PMID>
  </results_reference>
  <results_reference>
    <citation>Mauri T, Alban L, Turrini C, Cambiaghi B, Carlesso E, Taccone P, Bottino N, Lissoni A, Spadaro S, Volta CA, Gattinoni L, Pesenti A, Grasselli G. Optimum support by high-flow nasal cannula in acute hypoxemic respiratory failure: effects of increasing flow rates. Intensive Care Med. 2017 Oct;43(10):1453-1463. doi: 10.1007/s00134-017-4890-1. Epub 2017 Jul 31.</citation>
    <PMID>28762180</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 12, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high-flow nasal cannula</keyword>
  <keyword>flow setting</keyword>
  <keyword>peak tidal inspiratory flow</keyword>
  <keyword>hypoxemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified patient data will be shared upon reasonable request 3 months after publication.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>3 months after the study is published</ipd_time_frame>
    <ipd_access_criteria>the investigators need to send their IRB approved research protocol to Jie_li@rush.edu</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

